Legend Biotech Spon Ads Each Rep 2 Ord Shs (LEGN) Stock
Clinical stage biotech focused on blood cancer therapies. Here's the price, business snapshot, and what's worth knowing about Legend Biotech Spon Ads Each Rep 2 Ord Shs in July 2026.
Legend Biotech (LEGN) is a clinical‑stage biotechnology company focused on developing CAR‑T cell therapies for blood cancers, most notably multiple myeloma. Its lead asset, developed in partnership with a major pharmaceutical collaborator, represents the company’s core commercial and clinical value, with ongoing trials and post‑approval studies shaping future prospects. Investors should know the business is research‑intensive, with revenue largely tied to product approvals, manufacturing scale‑up and partner economics rather than steady recurring cash flows. The stock can be volatile around trial readouts, regulatory decisions and sales updates. Key considerations include clinical data, regulatory pathways, manufacturing capacity and partner milestones. Given the high scientific, regulatory and commercial risks in biotech, this summary is for educational purposes only and not personalised financial advice. Individual suitability depends on risk tolerance, time horizon and portfolio diversification; consider seeking regulated financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Legend Biotech's stock with a target price of $79.59, indicating strong growth potential.
Financial Health
Legend Biotech is performing well with strong revenue and profit margins, indicating solid business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring LEGN
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: 13 October 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: 3 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline progress to watch
Clinical readouts and regulatory milestones can re‑rate the company; outcomes are binary and can cause sharp moves, so monitor data timelines closely.
Manufacturing and scale
Commercial success depends on manufacturing scale and cost control as CAR‑T therapies are complex to produce; capacity constraints can affect revenues and margins.
Partner and market access
Partnerships help with commercial reach and risk sharing, but revenues and royalties depend on market uptake and pricing — performance can vary by region.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
